Table 1 Summary of assays performed
Test | Vial | Apparatus | Place of analysis | Normal range |
|---|---|---|---|---|
ROTEM® using the following reagents: EXTEM, FIBTEM®, INTEM, APTEM, NATEM, HEPTEM®, recording the following results: CT (Clotting time), CFT (Clot formation time), Alpha-Angle (AA), MCF (Maximum Clot Firmness), ML (Maximum Lysis). | 2.7mL citrate tubes for ROTEM® analysis (3.2% citrate, BD Vacutainer® Systems, Plymouth, UK) | ROTEM®, Pentapharm, Munich, Germany | Point-of-care laboratory, Intensive Care Unit | See Table 2. |
Multiplate® using the following agonists: adenosine diphosphate, collagen, thrombin receptor activator, recording the following results for each agonist: area under curve (AUC), aggregation (AU), velocity (AU/min). | 3.0mL Hirudin tubes. Dynabyte GmbH, Munich, Germany. | Multiplate®, Roche, Basel, Switzerland | See Table 2. | |
aPTT: activated partial thromboplastin time | 2.7mL citrate tubes (3.2% citrate, BD Vacutainer® Systems, Plymouth, UK) | PTT-Automate, Stago (Asnière sur Seine, France) | Hospital’s usual clinical chemistry laboratory | 28 to 45 seconds at the time of the study |
PT-INR: prothrombin time-international normalized ratio | Stago prothrombin complex assay, Stago calibrated by Equalis, (Uppsala, Sweden) | ≤1.2 | ||
Plc: platelet count | 3.0mL K2EDTA tubes (BD Vacutainer® Systems, Plymouth UK) | Sysmex XE 5000 cell counter, Sysmex Corp., (Kobe, Japan). | 165 to 387 million/mL and 145 to 387 million/mL for women and men respectively |